SBI2 Special Interest Group at SLAS 2017

The Society for Biomolecular Imaging and Informatics and SLAS will co-host the 2017 HCS/HCA Data and Informatics SIG on Tuesday, February 7th, 8:00 AM to 9:15 AM, Room 149AB, Washington Convention Center, Washington, DC

 

m-logo

"SLAS is a global community of more than 20,000 scientists—from academia, government and industry—collectively focused on leveraging the power of technology to achieve scientific objectives. We consider a primary part of our mission to unite great minds in science and technology for the advancement of all research."

 

Title: "Applying High Content Screening and Image Analysis techniques to 3D models of Drug Discovery.”  Paul A. Johnston1, O.J. Trask2, Carrie Lovitt3, and Dan LaBarbera4.

 

  1. Associate Professor, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy.
  2. Senior Application Scientist, Cellular Imaging & Analysis, PerkinElmer.
  3. Research Fellow, Discovery Biology, Eskitis Institute for Drug Discovery Griffith University (Nathan Campus), Queensland, Australia.
  4. Associate Professor of Drug Discovery and Medicinal Chemistry, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, AMC. Director of High Throughput Screening & Chemical Biology Core Facilities.

 

Paul A. Johnston, Title: “What’s all the fuss about 3D models and why do we care?”

 

  1. J. Trask, S Title: “Strategies and Considerations for HCS 3D imaging and analysis”

 

Carrie Lovitt, Title: “Generating 3D cancer models for drug discovery using HCS technology” Topics covered will include the technologies to support culturing cancer cells in the third dimension, miniaturization and automation of 3D cell culture models for early-stage drug discovery and endpoint measurements.

 

Dan LaBarbera, Title: “Colorectal cancer tumor organoids for therapeutic discovery and development.” Recently, there has been a boom in concerted multidisciplinary efforts by scientists and biomedical engineers with a vision of developing 3D ex vivo tissue models of human organ function, anatomy and disease. These 3D models are referred to as organoid, organotypic, or spheroid and are used interchangeably within the collective literature. Organoids have the distinct feature of self-assembly when relevant components are present such as extracellular matrix (ECM) proteins or fibroblast cells. We have developed an organoid culture and high-content analysis (HCA) methodology of colorectal cancer (CRC). This presentation will describe our latest research using CRC organoids to discover and develop targeted and personalized drug therapies effective against the malignant and metastatic phenotype in CRC.